Founding BeamLine

BeamLine Diagnostics was founded in March 2015 by Dr. Liberty Foreman and Dr. Katherine Willetts during the final stages of their PhDs in the clinical applications of infrared spectroscopy. Their aim is to bring their research from the university laboratory to the hospital clinic to provide simple and effective point-of-care solutions for a wide range of diseases.

Measuring Success

Between March 2015 and April 2016, the Company secured key partnerships and strong relationships with leading NHS trusts, cancer charities and hardware suppliers, and this network is continually expanding. Successes for the Company have included; being awarded an Innovate UK SMART grant; winning a place on the international Class of 2016 programme; reaching the finals of the OneStart Europe and Pitch@Palace 5.0 competitions, and semi-finals of the SPIE Startup Challenge 2015 for photonics technologies. In July 2017, BeamLine were shortlisted for the UKBAA Best Investment in Life Sciences award.

Our roadmap

In April 2016, BeamLine secured seed funding from Deepbridge Capital to build an industrial prototype of their first product for triaging GI biopsies. In December 2016, BeamLine won a Small Business Research Initiative (SBRI) development contract to begin expanding the product into other cancer areas. The Company went on to raise a further £650K in an oversubscribed investment round in April 2017 to begin the first 'in-clinic' trials.

Subscribe to our mailing list

* indicates required